Skip to content

US · HRMY · BIOTECHNOLOGY

Harmony Biosciences Holdings, Inc. (HRMY) intrinsic value and stock valuation

$32.59as of 2026-11-21 · Mkt cap 2.21B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Harmony Biosciences Holdings, Inc. DCF and intrinsic value

InvestorsCraft values HRMY with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from HRMY’s statements →

Harmony Biosciences Holdings, Inc. Graham Number

Graham Number: $30.66d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Plymouth Meeting, PA 19462 harmonybiosciences.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$868.5M+40.3% 5y CAGRd
20182025
Net income
$158.7M
20182025
Free cash flow
$347.9M
20182025
Total equity
$870.2M+55% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$868.5M$714.7M$582M$437.9M$305.4M
Operating income$208.5M$190.8M$192M$120.2M$87.5M
Net income$158.7M$145.5M$128.9M$181.5M$34.6M
EPSd$2.71M$2.51M$2.13M$2.97M$584.4K
Operating cash flow$348.2M$219.8M$219.4M$144.5M$98.6M
Capital expenditure-$-310K-$-1.15M-$-310K-$-170K-$-300K
Free cash flow$347.9M$218.7M$219.1M$144.3M$98.3M
Total assets$1.27B$999.2M$811.5M$673.9M$433.4M
Total debt$239.6M$181.4M$193.6M$191.7M$195.7M
Net debt-$-512.92M-$-271.6M-$-118.09M-$-52.14M-$-38.56M
Total equity$870.2M$659.2M$467M$402.8M$186.5M
Cash and short-term investments$775.3M$467.2M$353.5M$323.1M$234.3M
Income statement
20252024202320222021
Revenue$868.5M$714.7M$582M$437.9M$305.4M
Cost of revenue$198.3M$156.8M$121.2M$83.5M$55.5M
Gross profit$670.1M$557.9M$460.8M$354.4M$249.9M
Research and development expenses$189.6M$145.8M$76.1M$70.9M$30.4M
Selling, general and administrative expenses$272.1M$221.3M$192.7M$163.3M$132M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$461.6M$367.1M$268.8M$234.2M$162.4M
Cost and expenses$660M$523.9M$390M$317.7M$217.9M
Interest income$21.9M$18.5M$14.7M$3.13M$220K
Interest expense$14.7M$17.5M$23.8M$18.8M$24.2M
Depreciation and amortization$25.3M$24.1M$24.4M$23.4M$18.8M
Ebitda$255.1M$233.4M$221.5M$146.9M$80.5M
Operating income$208.5M$190.8M$192M$120.2M$87.5M
Total other income/expenses, net$6.59M$980K-$-18.63M-$-15.5M-$-50.1M
Income before tax$215.1M$191.8M$173.4M$104.7M$37.4M
Income tax expense$56.4M$46.3M$44.5M-$-76.78M$2.83M
Net income$158.7M$145.5M$128.9M$181.5M$34.6M
Weighted average shares outstanding$57.5M$56.9M$59.5M$59.2M$57.5M
Weighted average diluted shares outstanding$58.5M$57.9M$60.4M$61.1M$59.2M
Balance sheet
20252024202320222021
Cash and short-term investments$775.3M$467.2M$353.5M$323.1M$234.3M
Net receivables$96.8M$83M$74.1M$54.7M$34.8M
Inventory$5.36M$7.2M$5.36M$4.3M$4.43M
Total current assets$907M$579.3M$451.1M$400.3M$284.4M
Property, plant and equipment, net$5.34M$3.38M$370K$570K$4.12M
Goodwill and intangible assets$89.4M$113.3M$137.1M$161M$143.9M
Long-term investments$107.4M$108.9M$72.2M$22.6M$0.00
Total non-current assets$364.6M$420M$360.4M$273.6M$149M
Total assets$1.27B$999.2M$811.5M$673.9M$433.4M
Accounts payable$17.7M$13.7M$17.7M$3.79M$1M
Short-term debt$86.9M$17.6M$15M$2M$3.36M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$252.1M$175.1M$163.8M$78.9M$53.8M
Long-term debt$152.7M$163.8M$178.6M$189.7M$192.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$149.3M$165M$180.7M$192.2M$193.2M
Capital lease obligations$4.51M$2.14M$0.00$0.00$3.76M
Total liabilities$401.4M$340.1M$344.5M$271M$246.9M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings$160.9M$2.22M-$-143.28M-$-272.13M-$-453.6M
Accumulated other comprehensive income (loss)$350K$70K$0.00-$-150K$0.00
Total equity$870.2M$659.2M$467M$402.8M$186.5M
Total investments$130.2M$123.1M$114M$101.9M$0.00
Total debt$239.6M$181.4M$193.6M$191.7M$195.7M
Net debt-$-512.92M-$-271.6M-$-118.09M-$-52.14M-$-38.56M
Cash flow statement
20252024202320222021
Net income$158.7M$145.5M$128.9M$181.5M$34.6M
Depreciation and amortization$25.3M$24.1M$24.4M$25.1M$21.1M
Stock-based compensation$44.9M$42.6M$31.7M$26.9M$16.1M
Change in working capital$91.8M-$-7.32M$35M-$-6.89M$2.19M
Accounts receivable-$-13.75M-$-8.89M-$-19.4M-$-19.9M-$-12.67M
Inventory$1.84M-$-1.83M-$-1.07M$140K-$-610K
Accounts payable$3.95M-$-5.38M$8.95M$0.00$0.00
Net cash provided by operating activities$348.2M$219.8M$219.4M$144.5M$98.6M
Investments in property, plant and equipment-$-19.56M-$-1.15M-$-310K-$-170K-$-300K
Acquisitions, net$0.00-$-33.07M-$-36.97M$0.00$0.00
Net cash used for investing activities-$-39.65M-$-67.48M-$-46.44M-$-141.83M-$-100.3M
Common stock issued$10.2M$6.5M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00-$-100M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-9.05M-$-11M-$-105.55M$6.84M$7.42M
Net change in cash$299.5M$141.3M$67.4M$9.47M$5.68M
Cash at end of period$752.5M$453.3M$311.9M$244.5M$235.1M
Operating cash flow$348.2M$219.8M$219.4M$144.5M$98.6M
Capital expenditure-$-310K-$-1.15M-$-310K-$-170K-$-300K
Free cash flow$347.9M$218.7M$219.1M$144.3M$98.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Harmony Biosciences Holdings, Inc.

        Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.

        CEO
        Jeffrey Dayno
        Employees
        293
        Beta
        0.94

        Explore

        Frequently asked questions

        What is the intrinsic value of Harmony Biosciences Holdings, Inc. (HRMY)?

        Harmony Biosciences Holdings, Inc. (HRMY) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is HRMY undervalued?

        HRMY trades at a price of $32.59 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.